Therapeutic Delivery – Products

Lonza has launched an innovative new capsule solution for intestinal (enteric) drug delivery.

Lipid nanoparticles (LNPs) comprised of ionizable lipids can be used to deliver oligonucleotides to work as therapeutics or to stimulate the immune system. Detailed and sensitive characterization of the ionizable lipid and its related impurities is necessary to ensure quality, however, obtaining the level of detail needed is challenging with current LC-MS-based methodologies.

AMSBIO offer an extensive range of highly characterized, high purity exosomes for use as control standards in applications including marker assessment, immunocapture performance evaluation, exosome quantification, OMICS analysis, flow cytometry and electron microscopy.

Waters Corporation today announced expanded powder rheology capabilities for its TA Instruments HR Rheometers allowing scientists to make repeatable powder rheology measurements.

CapnoPharm is proud to announce its selection as a finalist of the prestigious Reuters Pharma Europe Award 2022 for its Cancer drug delivery innovation - Capnodrug® - in the Health Entrepreneur Award category.

The clinical success of CAR T-cell therapy has spurred increased interest and investments in the advanced therapeutics industry.

TetraScience has announced the evolution of its data cloud to include manufacturing and quality control data.

Biotium has announced the release of new ExoBrite Antibody Conjugates. These antibodies were curated specifically for optimal detection of exosome markers CD9, CD63 and CD81 in isolated exosomes or exosome extracts with little to no background.

MaxCyte, Inc. has announced the signing of a strategic platform license with LG Chem Ltd.

In recent years, interest in lipid nanoparticle (LNP) research has increased due to promising opportunities for RNA-based therapy and gene-editing technology, and LNPs are showing promise as nucleic acid delivery vehicles in the pharmaceutical industry.